Azoxystrobin efficacy in scalp health

Abstract

To provide improvements of scalp health, including decreasing the number of flakes on the scalp, decreasing inflammation on the scalp, and decreasing itch on the scalp as perceived.SOLUTION: The present invention is directed to a method of decreasing the number of flakes on a surface selected from the group consisting of skin, scalp, or human scalp, or combinations thereof, by applying a composition comprising 0.01% to 10% azoxystrobin to the surface, wherein there is a reduction in an adherent scalp flaking score (ASFS) by 4.7 units with a 45% reduction in flaking compared to a placebo control and a 30% reduction in flaking after 3 weeks of treatment.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention is directed to azoxystrobin, which provides improved scalp health, including reduced scalp flakes, reduced scalp inflammation, and reduced scalp itching sensation.The present invention is further directed to the use of azoxystrobin to provide an improved scalp barrier. [Background technology]

[0002] Dandruff and seborrheic dermatitis are human scalp and skin conditions that involve yeasts of the genus Malassezia as causative organisms for causing and / or exacerbating unhealthy scalp / skin symptoms.Topical antifungal agents are routinely used to develop consumer products to address these conditions, and finding antifungal agents that more effectively control the growth and activity of Malassezia on the scalp or skin is the focus of much research.Strobilurins represent one such class of antifungal agents used in agriculture for crop protection that has been little studied for controlling the growth of Malassezia and its associated skin diseases. Summary of the Invention [Problem to be solved by the invention]

[0003] The present invention has found that the specific synthetic strobilurin azoxystrobin is unique among other compounds in its class in its antifungal efficacy against Malassezia. Azoxystrobin has been evaluated on the scalps of consumers with dandruff, resulting in the elimination of flaking and the improvement of other scalp health symptoms. Topical antifungal drugs are often combined with anti-inflammatory drugs such as corticosteroids to most effectively manage symptoms such as inflammation and itching in severe conditions. Azoxystrobin has been found to have unexpected efficacy in improving overall scalp health alone when used to treat human scalps with dandruff conditions. These scalp health benefits include reduced inflammation and itching perception, benefits that cannot be predicted from its antifungal efficacy alone. [Means for solving the problem]

[0004] The present invention is directed to the use of azoxystrobin to reduce the number of flakes on a surface; to reduce surface itching as perceived by a user; to reduce the level of myeloperoxidase on a surface as an indicator of reduced oxidative stress and damage. The present invention is directed to the use of azoxystrobin, wherein the azoxystrobin is applied from a personal care composition such as a shampoo, conditioner, or leave-on treatment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0005] While the specification concludes with claims which particularly point out and distinctly claim the invention, it is believed the present invention will be better understood from the following description.

[0006] The present invention can include, consist of, or consist essentially of any of the essential elements and limitations of the invention described herein, as well as any additional or optional ingredients, components, or limitations described herein.

[0007] Unless otherwise specified, all percentages and ratios used herein are by weight of the total composition. Unless otherwise indicated, it is understood that all measurements are made at ambient conditions, where "ambient conditions" means conditions at about 25°C, less than about 1 atmosphere, and about 50% relative humidity (RH). All numerical ranges are inclusive of narrower ranges. The stated upper and lower range limits are combinable to create additional ranges not expressly stated.

[0008] The compositions of the present invention can comprise, consist essentially of, or consist of the essential and optional components described herein. As used herein, "consisting essentially of" means that the composition or component may contain additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed composition or method.

[0009] "Applying" or "application" as used in reference to a composition means applying or spreading a composition of the present invention onto keratinous tissue, such as hair.

[0010] By "dermatologically acceptable" it is meant that the composition or components being described are suitable for use in contact with human skin tissue without undue toxicity, incompatibility, instability, allergic response, and the like.

[0011] By "safe and effective amount" is meant an amount of a compound or composition sufficient to significantly induce a beneficial effect.

[0012] "Leave-on" in reference to a composition means a composition that is intended to be applied and left on the keratinous tissue. These leave-on compositions should be distinguished from compositions that are applied to the hair and then removed (within minutes) either by washing, rinsing, wiping, etc. Leave-on compositions exclude rinse-off applications such as shampoos, rinse-off conditioners, facial cleansers, hand washes, body washes, or personal cleansers. Leave-on compositions may be substantially free of cleansing or detergent surfactants. For example, a "leave-on composition" may be left on the keratinous tissue for at least 15 minutes. For example, a leave-on composition may contain less than 1% detergent surfactant, less than 0.5% detergent surfactant, or 0% detergent surfactant. However, the composition may contain emulsifiers, dispersants, or other processing surfactants that are not intended to provide any significant cleansing benefit when applied topically to the hair.

[0013] By "soluble" it is meant that at least about 0.1 g of solute dissolves in 100 mL of solvent at 25° C. and 1 atm pressure.

[0014] All percentages are by weight of the total composition unless otherwise specified. All ratios are by weight unless specifically stated otherwise. All ranges are inclusive and combinable. The number of significant digits does not represent a limitation on the amounts listed, nor does it represent a limitation on the precision of the measurements. The term "molecular weight" or "M.Wt." as used herein, unless otherwise specified, refers to weight average molecular weight. Weight average molecular weight can be measured by gel permeation chromatography. "QS" means quantity sufficient to make 100%.

[0015] As used herein, the terms "substantially free of" or "substantially free from" mean less than about 1%, or less than about 0.8%, or less than about 0.5%, or less than about 0.3%, or about 0%, by weight of the total composition.

[0016] As used herein, "hair" means mammalian hair, specifically the hair on the human head and scalp, including scalp hair, facial hair and body hair.

[0017] "Cosmetically acceptable," as used herein, means that the composition, formulation, or component being described is suitable for use in contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic reaction, etc. All compositions described herein that are intended for direct application to keratinous tissue are limited to being cosmetically acceptable.

[0018] As used herein, "derivatives" include, but are not limited to, amide, ether, ester, amino, carboxyl, acetyl, acid, salt, and / or alcohol derivatives of a given compound.

[0019] As used herein, "polymer" refers to a chemical substance formed from the polymerization of two or more monomers. As used herein, the term "polymer" includes all materials made by polymerization of monomers, as well as natural polymers. A polymer made of only one type of monomer is called a homopolymer. A polymer made of two or more different monomers is called a copolymer. The distribution of different monomers can be calculated statistically or block-by-block, both possibilities being suitable for the present invention. Unless otherwise stated, the term "polymer" as used herein includes all types of polymers, including homopolymers and copolymers.

[0020] Azoxystrobin and other strobilurins Azoxystrobin, CAS number: 131860-33-8, IUPAC: methyl-(E)-(2-{2-[6-(2-cyanophenoxy)-pyrimidin-4-yloxy]-phenyl}-3-methoxyacrylate), is an agricultural fungicide that belongs to the class of strobilurins. Strobilurins are either biosynthesized by various basidiomycete fungi, such as Strobilurus tenacellus and Oudemansiella mucida, or are modeled after natural strobilurins, retaining the primary β-methoxyacrylate toxophore. Some of the synthesized strobilurins have modified toxophores, such as methyl methoxyiminoacetate or methyl-N-methoxycarbamate. Among the synthetic strobilurin compounds are azoxystrobin (CAS number: 131860-33-8), cumoxystrobin (CAS number: 850881-70-8), dimoxystrobin (CAS number: 149961-52-4), enoxastrobin (CAS number: 238410-11-2), fluoxastrobin (CAS number: 193740-76-0), kresoxim-methyl (CAS number: 143390-89-0), mandestrobin (CAS number: 143390-89-0), and cyclohexanone (CAS number: 143390-89-0). Other examples include strobin (CAS number 173662-97-0), metominostrobin (CAS number 133408-50-1), orysastrobin (CAS number 248593-16-0), picoxystrobin (CAS number 117428-22-5), pyraclostrobin (CAS number 175013-18-0), pyraoxystrobin (CAS number 862588-11-2), and trifloxystrobin (CAS number 141517-21-7).

[0021] Azoxystrobin and other synthetic strobilurins control a wide range of plant fungal diseases and are widely used in crop protection worldwide. Strobilurins act by inhibiting mitochondrial respiration. The specific mechanism of action of azoxystrobin and other strobilurins is the inhibition of ubiquinol oxidation at the cytochrome b complex III of the electron transport chain (Q 0 site) and binds to cytochrome b and cytochrome c 1Other compounds with this specific mechanism of action include synthetic and naturally occurring derivatives of the major β-methoxyacrylate toxins known as oudemansins, first isolated from Oudemansiella mucida, synthetic and naturally occurring myxothiazoles from myxobacteria such as Myxococcus flavus, stigmatellin from myxobacteria such as Stigmatella aurantica, and the synthetic pesticides famoxadone and fenamidone.

[0022] As an agricultural fungicide, azoxystrobin has protective, curative, exterminating, translaminar and systemic action, inhibits spore germination and mycelial growth, and also exhibits antisporogenic activity. At the indicated application rates, azoxystrobin is effective against numerous plant pathogens, such as Erysiphe graminis, Puccinia spp., Lepiosphaeria nodorum, Septoria tritici, and Pyrenophora teres in temperate cereals; Pyricularia oryzae and Rhizoctonia solani in rice; Plasmopara viticola and Uncinula necator in grapevines; Sphaerotheca fuliginea and Pseudoperonospora cubensis in cucurbits; Phytophthora infestans and Alternaria solani in potatoes and tomatoes; Mycosphaerella arachidis, Rhizoctonia solani, and Sclerotium rolfsii in peanuts; Monilinia spp., and Cladosporium carpophilum in peaches; Pythium spp. and Rhizoctonia solani in turfgrass; and Mycosphaerella arachidis in bananas. spp.; Cladosporium caryigenum in pecan; Elsinoe fawcetii, Colletotrichum spp. and Guignardia citricarpa in citrus; Colletotrichum spp. and Hemileia vastatrix in coffee. Azoxystrobin is a solid substance that has low solubility in water.

[0023] Trade names for azoxystrobin include ABOUND FLOWABLE FUNGICIDE, Aframe, Azoxystar, Azoxyzone, AZteroid 1.65 SC Fungicide, AZURE AGRICULTURAL FUNGICIDE, Endow, QUADRIS FLOWABLE FUNGICIDE, Satori Fungicide, Strobe 2L, Willowood Azoxy 2SC, etc. Azoxystrobin is commercially available, for example, from Sigma-Aldrich (St. Louis, MO) and Ak Scientific, Inc. (Union City, CA).

[0024] In the present invention, the personal care compositions may include: from about 0.02% to about 10% azoxystrobin; from about 0.05% to about 2% azoxystrobin; from about 0.1% to about 1% azoxystrobin.

[0025] In the present invention, the personal care composition may comprise from about 0.02% to about 10% of a strobilurin; from about 0.05% to about 2% of a strobilurin; from about 0.1% to about 1% of a strobilurin.

[0026] In the present invention, the particle size of Azoxystrobin can be about 0.5 micrometers to about 200 micrometers; about 0.5 micrometers to about 100 micrometers; about 1 micrometer to about 50 micrometers; about 1 micrometer to about 25 micrometers, about 1 micrometer to about 10 micrometers, or about 1 micrometer to about 3 micrometers.

[0027] Shampoo Composition Detergent Surfactants The personal care composition may comprise greater than about 10% by weight of a surfactant system that provides cleaning performance to the composition, and may comprise greater than about 12% by weight of a surfactant system that provides cleaning performance to the composition. The surfactant system comprises an anionic surfactant, and / or a combination of anionic surfactants, and / or a combination of anionic surfactants with co-surfactants selected from the group consisting of amphoteric, zwitterionic, nonionic, and mixtures thereof. Various examples and descriptions of detersive surfactants are described in U.S. Patent No. 8,440,605, U.S. Patent Application Publication No. 2009 / 155383, and U.S. Patent Application Publication No. 2009 / 0221463, which are incorporated herein by reference in their entireties.

[0028] The personal care compositions may comprise from about 10% to about 25%, from about 10% to about 18%, from about 10% to about 14%, from about 10% to about 12%, from about 11% to about 20%, from about 12% to about 20%, and / or from about 12% to about 18% by weight of one or more surfactants.

[0029] Suitable anionic surfactants for use in the composition are alkyl and alkyl ether sulfates.Other suitable anionic surfactants are the water-soluble salts of organic sulfuric acid reaction products.Still other suitable anionic surfactants are the reaction products of fatty acids esterified with isethionic acid and neutralized with sodium hydroxide.Other similar anionic surfactants are described in U.S. Patent Nos. 2,486,921, 2,486,922, and 2,396,278, which are incorporated herein by reference in their entirety.

[0030] Exemplary anionic surfactants for use in personal care compositions include ammonium lauryl sulfate, ammonium laureth sulfate, ammonium C10-15 pareth sulfate, ammonium C10-15 alkyl sulfate, ammonium C11-15 alkyl sulfate, ammonium decyl sulfate, ammonium deceth sulfate, ammonium undecyl sulfate, ammonium undeceth sulfate, triethylamine lauryl sulfate, triethylamine laureth sulfate, triethanolamine lauryl sulfate, triethanolamine laureth sulfate, monoethanolamine lauryl sulfate, monoethanolamine laureth sulfate, diethanolamine lauryl sulfate, diethanolamine laureth sulfate, lauryl monoglyceride sodium sulfate, sodium lauryl sulfate, sodium laureth sulfate, sodium C10-15 pareth sulfate, sodium C10-15 alkyl sulfate, sodium C11-15 alkyl sulfate, sodium decyl sulfate, sodium deceth sulfate, sodium The anionic surfactants include sodium undecyl sulfate, sodium undecyl sulfate, potassium lauryl sulfate, potassium laureth sulfate, C10-15 potassium pareth sulfate, C10-15 potassium alkyl sulfate, C11-15 potassium alkyl sulfate, potassium decyl sulfate, potassium decyl sulfate, potassium undecyl sulfate, potassium undecyl sulfate, sodium lauryl sarcosinate, sodium lauroyl sarcosinate, lauryl sarcosine, cocoyl sarcosine, ammonium cocoyl sulfate, ammonium lauroyl sulfate, sodium cocoyl sulfate, sodium lauroyl sulfate, potassium cocoyl sulfate, potassium lauryl sulfate, triethanolamine lauryl sulfate, triethanolamine lauryl sulfate, monoethanolamine cocoyl sulfate, monoethanolamine lauryl sulfate, sodium tridecylbenzenesulfonate, sodium dodecylbenzenesulfonate, sodium cocoyl isethionate, and combinations thereof. The anionic surfactant may be sodium lauryl sulfate or sodium laureth sulfate.

[0031] The composition of the present invention also comprises a)R 1 O(CH 2 CHR 3 O) y SO3 M. b) CH 3 (CH 2 ) z CHR 2 CH 2 O(CH 2 CHR 3 O) y SO 3 M, and c) Mixtures of these (In the formula, R 1 is CH 3 (CH 2 ) 10 R 2 is H, or z and R 2 R represents a hydrocarbon group containing 1 to 4 carbon atoms so that the total number of carbon atoms in 3 is H or CH 3 wherein y is 0 to 7, and when y is not zero (0), the average value of y is about 1, and M is a monovalent or divalent positively charged cation.

[0032] Suitable anionic alkyl sulfate and alkyl ether sulfate surfactants include, but are not limited to, those having branched alkyl chains synthesized from C8-C18 branched alcohols which may be selected from the group consisting of Guerbet alcohols, aldol condensation derived alcohols, oxo alcohols, FT oxo alcohols and mixtures thereof. Non-limiting examples of 2-alkyl branched alcohols include 2-methyl-1-undecanol, 2-ethyl-1-decanol, 2-propyl-1-nonanol, 2-butyl-1-octanol, 2-methyl-1-dodecanol, 2-ethyl-1-undecanol, 2-propyl-1-decanol, 2-butyl-1-nonanol, 2-pentyl-1-octanol, 2-pentyl-1-heptanol, and those sold under the trade names LIAL® (Sasol), ISALCHEM. (Sasol), and NEODOL® (Shell), as well as Guerbet and aldol condensation derived alcohols such as 2-ethyl-1-hexanol, 2-propyl-1-butanol, 2-butyl-1-octanol, 2-butyl-1-decanol, 2-pentyl-1-nonanol, 2-hexyl-1-octanol, 2-hexyl-1-decanol, and those sold under the trade name ISOFOL® (Sasol), or as alcohol ethoxylates and alkoxylates under the trade names LUTENSOL XP® (BASF) and LUTENSOL XL® (BASF).

[0033] Anionic alkyl sulfates and alkyl ether sulfates can also include those synthesized from C8-C18 branched alcohols derived from butylene or propylene sold under the trade names EXXAL™ (Exxon) and Marlipal® (Sasol). This includes the subclass of anionic surfactants, sodium trideceth-n sulfate (STnS), where n is from about 0.5 to about 3.5. Exemplary surfactants of this subclass are sodium trideceth-2 sulfate and sodium trideceth-3 sulfate. The compositions of the present invention can also include sodium tridecyl sulfate.

[0034] The compositions of the present invention may also include anionic alkyl and alkyl ether sulfosuccinates and / or dialkyl and dialkyl ether sulfosuccinates and mixtures thereof. The dialkyl and dialkyl ether sulfosuccinates may be C6-15 linear or branched dialkyl or dialkyl ether sulfosuccinates. The alkyl moieties may be symmetrical (i.e., the same alkyl moieties) or asymmetrical (i.e., different alkyl moieties). Non-limiting examples include disodium lauryl sulfosuccinate, disodium laureth sulfosuccinate, sodium bistridecyl sulfosuccinate, sodium dioctyl sulfosuccinate, sodium dihexyl sulfosuccinate, sodium dicyclohexyl sulfosuccinate, sodium diamyl sulfosuccinate, sodium diisobutyl sulfosuccinate, linear bis(tridecyl) sulfosuccinate and mixtures thereof.

[0035] The personal care composition may include a co-surfactant. The co-surfactant may be selected from the group consisting of amphoteric surfactants, zwitterionic surfactants, nonionic surfactants, and mixtures thereof. The co-surfactant may include, but is not limited to, lauramidopropyl betaine, cocamidopropyl betaine, lauryl hydroxysultaine, sodium lauroamphoacetate, disodium cocoamphodiacetate, cocamide monoethanolamide, and mixtures thereof.

[0036] The personal care compositions may further comprise from about 0.25% to about 15%, from about 1% to about 14%, from about 2% to about 13% by weight of one or more amphoteric, zwitterionic, nonionic co-surfactants, or mixtures thereof.

[0037] Suitable amphoteric or zwitterionic surfactants for use in the personal care compositions herein include those well known for use in shampoos or other personal care cleansers. Non-limiting examples of suitable zwitterionic or amphoteric surfactants are described in U.S. Patent Nos. 5,104,646 and 5,106,609, which are incorporated herein by reference in their entireties.

[0038] Amphoteric co-surfactants suitable for use in the compositions include surfactants described as derivatives of aliphatic secondary and tertiary amines, in which the aliphatic groups can be linear or branched, one of the aliphatic substituents containing from about 8 to about 18 carbon atoms and one containing an anionic group such as a carboxy, sulfonate, sulfate, phosphate, or phosphonate. Suitable amphoteric surfactants include sodium cocaminopropionate, sodium cocaminodipropionate, sodium cocoamphoacetate, sodium cocoamphodiacetate, sodium cocoamphohydroxypropylsulfonate, sodium cocoamphopropionate, sodium cornamphopropionate, sodium lauraminopropionate, sodium lauroamphoacetate, sodium lauroamphodiacetate, sodium lauroamphohydroxypropylsulfonate, sodium lauroamphopropionate, sodium cornamphopropionate, sodium lauriminodipropionate, ammonium cocaminopropionate, ammonium cocaminodipropionate, ammonium cocoamphoacetate, ammonium cocoamphodiacetate, ammonium cocoamphohydroxypropylsulfonate, ammonium cocoamphopropionate, ammonium cornamphopropionate, ammonium lauraminopropionate, ammonium lauroamphoacetic acid, Ammonium lauroamphodiacetate, ammonium lauroamphohydroxypropylsulfonate, ammonium lauroamphopropionate, ammonium corn amphopropionate, ammonium lauriminodipropionate, triethanolamine cocaminopropionate, triethanolamine cocaminodipropionate, triethanolamine cocoamphoacetate, triethanolamine cocoamphohydroxypropylsulfonate, triethanolamine cocoamphopropionate, triethanolamine corn amphopropionate, triethanolamine lauraminopropionate, triethanolamine lauroamphoacetate, triethanolamine lauroamphohydroxypropylsulfonate, triethanolamine lauroamphopropionate, triethanolamine corn amphopropionate, triethanolamine lauraminodipropionate, triethanolamine lauroamphoacetate, triethanolamine lauroamphohydroxypropylsulfonate, triethanolamine lauroamphopropionate, triethanolamine corn amphopropionate, triethanolamine lauraminodipropionate, cocoamphodipropionic acid, disodium caproamphodiacetate,Disodium caproamphodipropionate, disodium capryloamphodiacetate, disodium capryloamphodipriopionate, disodium cocoamphocarboxyethyl hydroxypropyl sulfonate, disodium cocoamphodiacetate, disodium cocoamphodipropionate, disodium dicarboxyethyl cocopropylenediamine, disodium laureth-5 carboxyamphodiacetate, disodium lauriminodipropionate, disodium lauroamphodiacetate, disodium lauroamphodipropionate, disodium oleoamphodipropionate, disodium PPG-2-isodecyl-7 carboxyamphodiacetate, disodium lauraminopropionic acid, lauroamphodipropionic acid, lauryl aminopropyl glycine, lauryl diethylenediaminoglycine, and mixtures thereof.

[0039] The compositions may also include zwitterionic co-surfactants, which are derivatives of aliphatic quaternary ammonium, phosphonium, and sulfonium compounds, in which the aliphatic groups may be linear or branched, and one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic group, such as a carboxy, sulfonate, sulfate, phosphate, or phosphonate. The zwitterionic surfactant may be selected from the group consisting of cocamidoethyl betaine, cocamidopropylamine oxide, cocamidopropyl betaine, cocamidopropyl dimethylamino hydroxypropyl hydrolyzed collagen, cocamidopropyl dimonium hydroxypropyl hydrolyzed collagen, cocamidopropyl hydroxysultaine, cocobetaine amide amphopropionate, coco-betaine, coco-hydroxysultaine, coco / oleamidopropyl betaine, coco-sultaine, lauramidopropyl betaine, lauryl betaine, lauryl hydroxysultaine, lauryl sultaine, and mixtures thereof.

[0040] Suitable nonionic surfactants for use in the present invention include those described in McCutcheion's Detergents and Emulsifiers, North American edition (1986), Allured Publishing Corp., and McCutcheion's Functional Materials, North American edition (1992). Suitable nonionic surfactants for use in the personal care compositions of the present invention include, but are not limited to, polyoxyethylenated alkylphenols, polyoxyethylenated alcohols, polyoxyethylenated polyoxypropylene glycols, glyceryl esters of alkanoic acids, polyglyceryl esters of alkanoic acids, propylene glycol esters of alkanoic acids, sorbitol esters of alkanoic acids, polyoxyethylenated sorbitol esters of alkanoic acids, polyoxyethylene glycol esters of alkanoic acids, polyoxyethylenated alkanoic acids, alkanolamides, N-alkylpyrrolidones, alkyl glycosides, alkyl polyglucosides, alkyl amine oxides, and polyoxyethylenated silicones.

[0041] The co-surfactant can be a non-ionic surfactant selected from the group of alkanolamides including cocamide, cocamide methyl MEA, cocamide DEA, cocamide MEA, cocamide MIPA, lauramide DEA, lauramide MEA, lauramide MIPA, myristamide DEA, myristamide MEA, PEG-20 cocamide MEA, PEG-2 cocamide, PEG-3 cocamide, PEG-4 cocamide, PEG-5 cocamide, PEG-6 cocamide, PEG-7 cocamide, PEG-3 lauramide, PEG-5 lauramide, PEG-3 oleamide, PPG-2 cocamide, PPG-2 hydroxyethyl cocamide, PPG-2 hydroxyethyl isostearamide, and mixtures thereof.

[0042] Representative polyoxyethylenated alcohols include alkyl chains ranging from C9 to C16 and having from about 1 to about 110 alkoxy groups, including, but not limited to, laureth-3, laureth-23, ceteth-10, steareth-10, steareth-100, beheneth-10, and those commercially available from Shell Chemicals (Houston, Texas) under the trade names Neodol® 91, Neodol® 23, Neodol® 25, Neodol® 45, Neodol® 135, Neodo® 167, Neodol® PC100, Neodol® PC200, Neodol® PC600, and mixtures thereof.

[0043] Also commercially available are the polyoxyethylene aliphatic ethers available from Uniqema (Wilmington, Delaware) under the trade name Brij®, including, but not limited to, Brij® 30, Brij® 35, Brij® 52, Brij® 56, Brij® 58, Brij® 72, Brij® 76, Brij® 78, Brij® 93, Brij® 97, Brij® 98, Brij® 721, and mixtures thereof.

[0044] Suitable alkyl glycosides and alkyl polyglucosides can be represented by the formula (S)nOR, where S is a sugar moiety such as glucose, fructose, mannose, galactose, etc., n is an integer from about 1 to about 1000, and R is a C8-C30 alkyl group. Examples of long chain alcohols from which the alkyl group can be derived include decyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, and the like. Examples of these surfactants include alkyl polyglucosides, where S is a glucose moiety, R is a C8-20 alkyl group, and n is an integer from about 1 to about 9. Commercially available examples of these surfactants include decyl polyglucosides and lauryl polyglucosides available from Cognis (Ambler, Pa.) under the trade names APG® 325CS, APG® 600CS, and APG® 625CS. Also useful herein are sucrose ester surfactants such as sucrose cocoate and sucrose laurate, as well as alkyl polyglucosides available from Dow Chemical Company (Houston, Tx) under the trade names Triton™ BG-10 and Triton™ CG-110.

[0045] Other nonionic surfactants suitable for use in the present invention are glyceryl esters and polyglyceryl esters, including, but not limited to, glyceryl monoesters, such as glyceryl oleate, glyceryl monostearate, glyceryl monopalmitate, glyceryl monobehenate, and mixtures thereof, and polyglyceryl esters of C12-22 saturated, unsaturated and branched fatty acids, such as polyglyceryl-4 isostearate, polyglyceryl-3 oleate, polyglyceryl-2-sesquioleate, triglyceryl diisostearate, diglyceryl monooleate, tetraglyceryl monooleate, and mixtures thereof.

[0046] Also useful herein as nonionic surfactants are sorbitan esters. Sorbitan esters of C12-22 saturated, unsaturated, and branched fatty acids are useful herein. These sorbitan esters typically include mixtures of esters such as monoesters, diesters, triesters, etc. Representative examples of suitable sorbitan esters include sorbitan monolaurate (SPAN® 20), sorbitan monopalmitate (SPAN® 40), sorbitan monostearate (SPAN® 60), sorbitan tristearate (SPAN® 65), sorbitan monooleate (SPAN® 80), sorbitan trioleate (SPAN® 85), and sorbitan isostearate.

[0047] Also suitable for use herein are alkoxylated derivatives of sorbitan esters, including, but not limited to, polyoxyethylene (20) sorbitan monolaurate (Tween® 20), polyoxyethylene (20) sorbitan monopalmitate (Tween® 40), polyoxyethylene (20) sorbitan monostearate (Tween® 60), polyoxyethylene (20) sorbitan monooleate (Tween® 80), polyoxyethylene (4) sorbitan monolaurate (Tween® 21), polyoxyethylene (4) sorbitan monostearate (Tween® 61), polyoxyethylene (5) sorbitan monooleate (Tween® 81), and mixtures thereof, all available from Uniqema.

[0048] Also suitable for use herein are alkylphenol ethoxylates, including, but not limited to, nonylphenol ethoxylates (Tergitol™ NP-4, NP-6, NP-7, NP-8, NP-9, NP-10, NP-11, NP-12, NP-13, NP-15, NP-30, NP-40, NP-50, NP-55, NP-70, available from Dow Chemical Company, Houston, Tex.) and octylphenol ethoxylates (Triton™ X-15, X-35, X-45, X-114, X-100, X-102, X-165, X-305, X-405, X-705, available from Dow Chemical Company, Houston, Tex.).

[0049] Also suitable for use herein are the tertiary alkyl amine oxides, including lauramine oxide and cocamine oxide.

[0050] Non-limiting examples of other anionic surfactants, zwitterionic surfactants, amphoteric surfactants, and additional nonionic surfactants suitable for use in the personal care compositions are described in McCutcheon's "Emulsifiers and Detergents, 1989 Annual" (published by MC Publishing Co.), and U.S. Pat. Nos. 3,929,678, 2,658,072, 2,438,091, and 2,528,378, which are incorporated by reference in their entireties.

[0051] Suitable surfactant combinations include an average weight percent alkyl branching of about 0.5% to about 30%, alternatively about 1% to about 25%, alternatively about 2% to about 20%. The surfactant combination can have a cumulative average C8-C12 alkyl chain length weight percent of about 7.5% to about 25%, alternatively about 10% to about 22.5%, alternatively about 10% to about 20%. The surfactant combination can have an average C8-C12 / C13-C18 alkyl chain ratio of about 3 to about 200, alternatively about 25 to about 175.5, alternatively about 50 to about 150, alternatively about 75 to about 125.

[0052] Adhesion aid The shampoo compositions of the present invention may further comprise a deposition aid such as a cationic polymer or cationic deposition polymer. The cationic polymers useful herein are those having an average molecular weight of at least about 5,000, alternatively from about 10,000 to about 10,000,000, alternatively from about 100,000 to about 2,000,000.

[0053] The cationic polymer may include, but is not limited to, a cationic guar polymer having a weight average molecular weight of less than 2,200,000 g / mol, or from about 150,000 to about 2,200,000 g / mol, or from about 200,000 to about 2,200,000 g / mol, or from about 300,000 to about 1,200,000 g / mol, or from about 750,000 (750,000 thousand) to about 1,000,000 g / mol. The cationic guar polymer may have a charge density of about 0.2 to about 2.2 meq / g, or from about 0.3 to about 2.0 meq / g, or from about 0.4 to about 1.8 meq / g, or from about 0.5 meq / g to about 1.8 meq / g.

[0054] The cationic guar polymer may have a weight average molecular weight of less than about 1,500,000 g / mol and has a charge density of from about 0.1 meq / g to about 2.5 meq / g. The cationic guar polymer may have a weight average molecular weight of less than 900,000 g / mol, or from about 150,000 to about 800,000 g / mol, or from about 200,000 to about 700,000 g / mol, or from about 300,000 to about 700,000 g / mol, or from about 400,000 to about 600,000 g / mol, or from about 150,000 to about 800,000 g / mol, or from about 200,000 to about 700,000 g / mol, or from about 300,000 to about 700,000 g / mol, or from about 400,000 to about 600,000 g / mol. The cationic guar polymer may have a charge density of from about 0.2 to about 2.2 meq / g, or from about 0.3 to about 2.0 meq / g, or from about 0.4 to about 1.8 meq / g, or from about 0.5 meq / g to about 1.5 meq / g.

[0055] Suitable cationic polymers include, for example, copolymers of vinyl monomers with cationic amine or quaternary ammonium functional groups and water-soluble spacer monomers (e.g., acrylamide, methacrylamide, alkyl and dialkyl acrylamide, alkyl and dialkyl methacrylamide, alkyl acrylate, alkyl methacrylate, vinyl caprolactone, and vinyl pyrrolidone). Other suitable spacer monomers include vinyl esters, vinyl alcohol (made by hydrolysis of polyvinyl acetate), maleic anhydride, propylene glycol, and ethylene glycol. Other suitable cationic polymers useful herein include, for example, cationic cellulose, cationic starch, and cationic guar gum. A non-limiting example of a cationic polymer is guar hydroxypropyltrimonium chloride.

[0056] The cationic polymer may be included in the hair care compositions of the present invention at a level of from about 0.001% to about 10% by weight. In the present invention, the cationic polymer may be present in an amount up to about 5% by weight based on the weight of the composition.

[0057] Aqueous Carrier The personal care composition comprises an aqueous carrier. Thus, the formulation of the personal care composition can be in the form of a pourable liquid (under ambient conditions). As such, such compositions typically comprise an aqueous carrier, which is present at a level of about 20% to about 95% by weight, or about 60% to about 85% by weight. The aqueous carrier may comprise water or a miscible mixture of water and an organic solvent, and in one embodiment, water with minimal or no significant concentrations of organic solvent, especially when incidentally incorporated into the composition as a minor component of other ingredients.

[0058] Aqueous carriers useful in personal care compositions include water and aqueous solutions of lower alkyl alcohols and polyhydric alcohols.Lower alkyl alcohols useful herein are monohydric alcohols having 1 to 6 carbons, in one embodiment, ethanol and isopropanol.Polyhydric alcohols useful herein include propylene glycol, dipropylene glycol, hexylene glycol, glycerin, and propanediol.

[0059] emulsifier If the personal care composition does not include a gel matrix, the 1,2-diol can be pre-emulsified and then added to the personal care composition. The selection of an emulsifier for each conditioning active is guided by the emulsifier's hydrophilic-lipophilic-balance value (HLB value). The preferred range of HLB values ​​is 6-16, more preferably 8-14. Emulsifiers with an HLB greater than 10 are water-soluble. Emulsifiers with low HLB are fat-soluble. A mixture of two or more emulsifiers may be used to obtain a suitable HLB value. Suitable emulsifiers include nonionic, cationic, anionic and amphoteric emulsifiers.

[0060] Rheology Modifiers / Thickeners The above personal care compositions may also contain one or more rheology modifiers / thickeners that adjust the rheological characteristics of the composition for better feel, properties during use, and suspension stability of the composition. For example, the rheological properties are adjusted so that the composition remains homogeneous during storage and transportation, and does not drip onto other areas of the body, clothing, or furniture during use, which is undesirable. Any suitable rheology modifier can be used. Additionally, the leave-on treatment may contain about 0.01% to about 3% of the rheology modifier, or alternatively about 0.1% to about 1% of the rheology modifier.

[0061] The one or more rheology modifiers may be selected from the group consisting of polyacrylamide thickeners, cationically modified polysaccharides, associative thickeners, and mixtures thereof. Associative thickeners include a wide variety of classes of materials such as, for example, hydrophobically modified cellulose derivatives; hydrophobically modified alkoxylated urethane polymers such as PEG-150 / decyl alcohol / SMDI copolymer, PEG-150 / stearyl alcohol / SMDI copolymer, polyurethane-39; hydrophobically modified alkali swellable emulsions such as hydrophobically modified polypolyacrylates, hydrophobically modified polyacrylic acids, and hydrophobically modified polyacrylamides; hydrophobically modified polyethers. These materials may have a hydrophobic portion that may be selected from cetyl, stearyl, oleayl, and combinations thereof, and a hydrophilic portion of repeating ethylene oxide groups having 10 to 300, alternatively 30 to 200, alternatively 40 to 150 repeat units. Examples of this category include PEG-120-methyl glucose dioleate, PEG-(40 or 60) sorbitan tetraoleate, PEG-150 pentaerythrityl tetrastearate, PEG-55 propylene glycol oleate, PEG-150 distearate.

[0062] Non-limiting examples of additional rheology modifiers include acrylamide / ammonium acrylate copolymer (and) polyisobutene (and) polysorbate 20; acrylamide / sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80; acrylates copolymer; acrylates / beheneth-25 methacrylate copolymer; acrylates / C10-C30 alkyl acrylate crosspolymer; acrylates / steareth-20 itaconate copolymer; ammonium polyacrylate / isohexadecane / PEG-40 castor oil; C12-16 alkyl PEG-2 hydroxypropyl hydroxyethyl ethyl cellulose (HM-EHEC); carbomer; crosslinked polyvinylpyrrolidone (PVP); dibenzylidene sorbitol; hydroxyethyl ethyl cellulose (EHEC); hydroxypropyl ethyl cellulose (HM- ... Examples of suitable polyacrylate crosspolymers include: pyryl methylcellulose (HPMC); hydroxypropyl methylcellulose (HPMC); hydroxypropyl cellulose (HPC); methylcellulose (MC); methylhydroxyethyl cellulose (MEHEC); PEG-150 / decyl alcohol / SMDI copolymer; PEG-150 / stearyl alcohol / SMDI copolymer; polyacrylamide / C13-14 isoparaffin / laureth-7; polyacrylate 13 / polyisobutene / polysorbate 20; polyacrylate crosspolymer-6; polyamide-3; polyquaternium-37 (and) hydrogenated polydecene (and) trideceth-6; polyurethane-39; sodium acrylate / acryloyldimethyltaurate / dimethylacrylamide; crosspolymer (and) isohexadecane (and) polysorbate 60; and sodium polyacrylate.Exemplary commercially available rheology modifiers include ACULYN™ 28, Klucel M CS, Klucel H CS, Klucel G CS, SYLVACLEAR AF1900V, SYLVACLEAR PA1200V, Benecel E10M, Benecel K35M, Optasense RMC70, ACULYN™ 33, ACULYN™ 46, ACULYN™ 22, ACULYN™ 44, Carbopol Ultrez 20, Carbopol Ultrez 21, Carbopol Ultrez 10, Carbopol 1342, Sepigel™ 305, Simulgel™ 600, Sepimax Zen, and / or combinations thereof.

[0063] A non-exhaustive list of thickening agents suitable for use herein includes xanthan, guar, hydroxypropyl guar, scleroglucan, methylcellulose, ethylcellulose (commercially available as Aquacote®), hydroxyethylcellulose (Natrosol®), carboxymethylcellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, hydroxybutyl methylcellulose, hydroxypropyl cellulose (Klucel®), hydroxyethyl ethylcellulose, cetyl hydroxyethylcellulose (Natrosol® Plus 330), N-vinylpyrollidone (Povidone®), acrylates / ceteth-20 itaconate copolyester. polymers (Structure® 3001), hydroxypropyl starch phosphate (Structure® ZEA), polyethoxylated urethane or polycarbamyl polyglycol esters (e.g., PEG-150 / Decyl / SMDI Copolymer = Aculyn® 44), PEG-150 / Stearyl / SMDI Copolymer = Aculyn 46®, trihydroxystearin (Thixcin®) acrylate copolymers (e.g., Aculyn® 33) or hydrophobically modified acrylate copolymers (e.g., Acrylates / Steareth-20 Methacrylate Copolymer = Aculyn® 22), and fatty alcohols (such as cetyl alcohol and stearyl alcohol), and combinations thereof.

[0064] Conditioner Composition The personal care composition of the present invention can be a hair conditioner, which provides desirable benefits to the consumer upon shampooing, such as moisturizing feel, combability, color retention, protection from hair damage, damage repair, dry feel, anti-frizz effect, in addition to the benefit of anti-dandruff effect on the scalp.

[0065] The conditioner composition may include a rinse-off conditioner. Additionally, the conditioner composition may include other optional ingredients such as silicone or organic conditioning agents, hair health actives, anti-dandruff actives, and other ingredients.

[0066] Hair conditioners are typically applied to hair after rinsing the shampoo composition from the hair. The conditioner compositions described herein provide the consumer with the desired hair conditioning in addition to anti-dandruff benefits.

[0067] The conditioning compositions described herein can also include a conditioner gel matrix that includes (1) one or more high melting point fatty compounds, (2) a cationic surfactant system, and (3) a second aqueous carrier. After applying the conditioner composition to the hair, water is used to rinse the conditioner from the hair.

[0068] A. Cationic surfactant system The conditioner gel matrix of the conditioner composition comprises a cationic surfactant system. The cationic surfactant system can be one cationic surfactant or a mixture of two or more cationic surfactants. The cationic surfactant system can be selected from mono-long alkyl quaternized ammonium salts; a combination of mono-long alkyl quaternized ammonium salts and di-long alkyl quaternized ammonium salts; mono-long alkyl amidoamine salts; a combination of mono-long alkyl amidoamine salts and di-long alkyl quaternized ammonium salts, a combination of mono-long alkyl amidoamine salts and mono-long alkyl quaternized ammonium salts.

[0069] The cationic surfactant system may be included in the composition at levels of from about 0.1% to about 10%, from about 0.5% to about 8%, from about 0.8% to about 5%, and from about 1.0% to about 4% by weight.

[0070] Mono long chain alkyl quaternary ammonium salt The monoalkyl quaternized ammonium salt cationic surfactants useful herein are those having one long alkyl chain having about 22 carbon atoms, which may be a C22 alkyl group. The remaining groups attached to the nitrogen are independently selected from alkyl groups of 1 to about 4 carbon atoms, or alkoxy, polyoxyalkylene, alkylamido, hydroxyalkyl, aryl, or alkylaryl groups having up to about 4 carbon atoms.

[0071] The mono long chain alkyl quaternized ammonium salts useful herein have the formula (I):

[0072] [ka] (In the formula, R 75 , R 76 , R 77 , and R 78 is selected from an alkyl group of 22 carbon atoms, or an aromatic group, an alkoxy group, a polyoxyalkylene group, an alkylamido group, a hydroxyalkyl group, an aryl group, or an alkylaryl group having up to about 30 carbon atoms; R 75 , R 76 , R 77 , and R 78 the remainder are independently selected from an alkyl group of 1 to about 4 carbon atoms, or an alkoxy group having up to about 4 carbon atoms, a polyoxyalkylene group, an alkylamido group, a hydroxyalkyl group, an aryl group, or an alkylaryl group; and X - R has a salt-forming anion, such as one selected from halogens (e.g., chloride, bromide), acetate, citrate, lactate, glycolate, phosphate, nitrate, sulfonate, sulfate, alkyl sulfate, and alkyl sulfonate groups. The alkyl groups may contain, in addition to carbon and hydrogen atoms, ether and / or ester linkages, as well as other groups such as amino groups. Longer chain alkyl groups, e.g., those having about 22 carbons or more, may be saturated or unsaturated. R 75 , R 76 , R77 and R 78 may be selected from an alkyl group of about 22 carbon atoms; 75 , R 76 , R 77 and R 78 The remainder of the 3 , C 2 H 5 , C 2 H 4 OH and mixtures thereof, X is selected from Cl, Br, CH 3 OSO 3 , C 2 H 5 OSO 3 and mixtures thereof.

[0073] Non-limiting examples of such mono-long chain alkyl quaternized ammonium salt cationic surfactants include behenyl trimethyl ammonium salts.

[0074] Mono long chain alkyl amidoamine salt Mono-long chain alkylamines are also suitable as cationic surfactants. Primary, secondary, and tertiary aliphatic amines are useful. Particularly useful are tertiary amidoamines with alkyl groups of about 22 carbons. Exemplary tertiary amidoamines include behenamidopropyl dimethylamine, behenamidopropyl diethylamine, behenamidoethyl diethylamine, behenamidoethyl dimethylamine. Amines useful in the present invention are disclosed in U.S. Pat. No. 4,275,055 (Nachtigal et al.). These amines may also be used in combination with acids such as λ-glutamic acid, lactic acid, hydrochloric acid, malic acid, succinic acid, acetic acid, fumaric acid, tartaric acid, citric acid, λ-glutamic acid hydrochloride, maleic acid, and mixtures thereof, which may be λ-glutamic acid, lactic acid, and / or citric acid. The amines herein may be partially neutralized with any acid at a molar ratio of amine to acid of about 1:0.3 to about 1:2 and / or about 1:0.4 to about 1:1.

[0075] Di-long chain alkyl quaternary ammonium salt The di-long alkyl quaternized ammonium salt can be combined with a mono-long alkyl quaternized ammonium salt or a mono-long alkyl amidoamine salt. It is believed that such a combination can provide an easier rinsing sensation than the use of the mono-long alkyl quaternized ammonium salt or the mono-long alkyl amidoamine salt alone. In such a combination with the mono-long alkyl quaternized ammonium salt or the mono-long alkyl amidoamine salt, the di-long alkyl quaternized ammonium salt is used at a level such that the weight percent of the di-alkyl quaternized ammonium salt in the cationic surfactant system is in the range of about 10% to about 50% and / or about 30% to about 45%.

[0076] Di-long chain alkyl quaternized ammonium salt cationic surfactants useful herein are those having two long alkyl chains of about 22 carbon atoms. The remaining groups attached to the nitrogen are independently selected from alkyl groups of 1 to about 4 carbon atoms, or alkoxy, polyoxyalkylene, alkylamido, hydroxyalkyl, aryl, or alkylaryl groups having up to about 4 carbon atoms.

[0077] The dilong chain alkyl quaternized ammonium salts useful herein have the formula (II):

[0078] [ka] (In the formula, R 75 , R 76 , R 77 and R 78 two of R are selected from alkyl groups from 22 carbon atoms or aromatic groups, alkoxy groups, polyoxyalkylene groups, alkylamide groups, hydroxyalkyl groups, aryl groups, or alkylaryl groups having up to about 30 carbon atoms; 75 , R 76 , R 77 , and R 78the remainder are independently selected from an alkyl group of 1 to about 4 carbon atoms, or an alkoxy group having up to about 4 carbon atoms, a polyoxyalkylene group, an alkylamido group, a hydroxyalkyl group, an aryl group, or an alkylaryl group; and X - R has a salt-forming anion, such as one selected from halogens (e.g., chloride, bromide), acetate, citrate, lactate, glycolate, phosphate, nitrate, sulfonate, sulfate, alkyl sulfate, and alkyl sulfonate groups. The alkyl groups may contain, in addition to carbon and hydrogen atoms, ether and / or ester linkages, as well as other groups such as amino groups. Longer chain alkyl groups, e.g., those having about 22 carbons or more, may be saturated or unsaturated. R 75 , R 76 , R 77 and R 78 may be selected from alkyl groups of from 22 carbon atoms; 75 , R 76 , R 77 and R 78 The remainder of the 3 , C 2 H 5 , C 2 H 4 OH and mixtures thereof, X is selected from Cl, Br, CH 3 OSO 3 , C 2 H 5 OSO 3 and mixtures thereof.

[0079] Examples of such dialkyl quaternized ammonium salt cationic surfactants include dialkyl (C22) dimethyl ammonium chloride, ditallow alkyl dimethyl ammonium chloride, and dihydrogenated tallow alkyl dimethyl ammonium chloride. Examples of such dialkyl quaternized ammonium salt cationic surfactants include asymmetric dialkyl quaternized ammonium salt cationic surfactants.

[0080] B. High melting point aliphatic compounds The conditioner gel matrix of the conditioner composition comprises one or more high melting point fatty compounds. The high melting point fatty compounds useful herein can have a melting point of 25°C or higher and are selected from the group consisting of fatty alcohols, fatty acids, fatty alcohol derivatives, fatty acid derivatives, and mixtures thereof. Those skilled in the art will understand that the compounds disclosed in this section of the specification may in some cases belong to more than one classification (e.g., some fatty alcohol derivatives may also be classified as fatty acid derivatives). However, the classification given is not intended to limit the particular compound, but is made so for the convenience of classification and nomenclature. Furthermore, those skilled in the art will understand that certain compounds with certain carbon atoms may have a melting point below 25°C, depending on the number and position of double bonds and the length and position of branches. Such compounds with low melting points are not intended to be included in this section. Non-limiting examples of high melting point compounds can be found in the International Cosmetic Ingredient Dictionary, Fifth Edition, 1993, and the CTFA Cosmetic Ingredient Handbook, Second Edition, 1992.

[0081] Among various high melting point fatty compounds, fatty alcohols are suitable for use in the conditioner composition.The fatty alcohols useful herein are those having about 14 to about 30 carbon atoms, about 16 to about 22 carbon atoms.These fatty alcohols are saturated and may be straight or branched chain alcohols.Suitable fatty alcohols include, for example, cetyl alcohol, stearyl alcohol, behenyl alcohol, and mixtures thereof.

[0082] High-purity single compound high melting point fatty compounds can be used. Pure fatty alcohol single compound can also be used, selected from the group of pure cetyl alcohol, stearyl alcohol, and behenyl alcohol. In this specification, "pure" means that the compound has a purity of at least about 90% and / or at least about 95%. These high-purity single compounds provide good rinsing from hair when consumers rinse the composition.

[0083] The high melting point fatty compounds may be included in the conditioner composition at a level of from about 0.1% to about 20%, alternatively from about 1% to about 15%, alternatively from about 1.5% to about 8%, by weight of the composition in view of providing improved conditioning benefits such as smoothness during application to wet hair and softness and moisturization on dry hair.

[0084] Leave-on treatment The personal care compositions of the present invention may be leave-on treatments that provide the consumer with desired hair conditioning or styling benefits in addition to the anti-dandruff benefits to the scalp.

[0085] The leave-on treatment compositions may include dry shampoos, mousses, pastes, gels, and milks. The leave-on treatments may also include (1) one or more rheology modifiers. In addition, the leave-on treatments may include pother optional ingredients such as silicone or organic conditioning agents, thickeners, hair health actives, anti-dandruff actives, and other ingredients.

[0086] Thus, the leave-on treatment formulation may be in the form of a pourable liquid (under ambient conditions).

[0087] If the leave-on composition does not include a gel matrix, the composition is preferably pre-emulsified before being added to the personal care composition.If the leave-on composition does not include a gel matrix, the composition preferably also includes a rheology modifier / thickener.

[0088] In the present invention, the leave-on treatment may involve application of a 1% w / w solution of these materials in a mixture of water, emulsifier and thickener (Sepigel 305).Preferred materials include, for 1-2-diols, 1,2-decanediol, 1,2-dodecanediol, 1,2-octanediol, and for solid particles, silica silylate, salicylic acid, 2,4-dihydroxybenzoic acid, 4-chlororesorcinol, 1,2,4-trihydroxybenzene and zinc carbonate.

[0089] The azoxystrobin-containing product may be liquid, solid, or powder, or a combination thereof, and may be dispensed from a container or may be a single-use product. Non-limiting examples of single-use products may include individual products in the form of solid foams, capsules, pills, pods, sheets, films, tablets, compressed powders, encapsulated liquids, pouches, or fibers. Powders may be dispensed from a container or delivered from an aerosol as dry shampoo. The product may also be a liquid cleaning composition for cleaning the skin or hair, including shampoos, conditioners, body washes, or facial cleansers, which are rinsed off. Personal care products may be deodorants in the form of solids or aerosols or pump sprays.

[0090] pH The above personal care compositions may also include one or more pH adjusting substances. The compositions may have a pH in the range of about 2 to about 10 at 25° C. Rinse-off conditioner compositions and / or leave-on treatments may have a pH in the range of about 2 to about 6, alternatively about 3.5 to about 5, alternatively about 5.25 to about 7.

[0091] The above personal care compositions may further comprise one or more pH buffering agents.Suitable buffering agents are well known in the art and include, for example, ammonia / ammonium acetate mixtures and monoethanolamine (MEA).Rinse-off conditioner compositions may also comprise citric acid, which acts as a buffering agent.

[0092] Optional Ingredients The conditioner compositions, pre-wash compositions and / or leave-on treatments described herein may optionally contain one or more additional ingredients known for use in personal care or personal care products, provided that the additional ingredients are physically and chemically compatible with the essential ingredients described herein or do not otherwise unduly impair the stability, aesthetics or performance of the product. Such additional ingredients are most typically those described in references such as CTFA Cosmetic Ingredient Handbook, Second Edition, The Cosmetic, Toiletries, and Fragrance Association, Inc. 1988, 1992. The individual concentrations of such additional ingredients may range from about 0.001% to about 10% by weight of the personal care composition.

[0093] Non-limiting examples of additional ingredients for use in personal care compositions include conditioning agents, natural cationic deposition polymers, synthetic cationic deposition polymers, other anti-dandruff agents, particles, suspending agents, paraffinic hydrocarbons, propellants, viscosity modifiers, dyes, non-volatile solvents or diluents (water soluble and water insoluble), pearlescent aids, foaming agents, additional surfactants or non-ionic co-surfactants, pediculocides, pH adjusters, fragrances, preservatives, proteins, skin actives, sunscreens, UV absorbers, and vitamins.

[0094] 1. Conditioning agents The personal care composition may comprise one or more conditioning agents. Conditioning agents include materials that are used to provide specific conditioning benefits to hair. The conditioning agents useful in the personal care composition of the present invention typically comprise water-insoluble, water-dispersible, non-volatile liquids that form emulsified liquid particles. The conditioning agents suitable for use in the personal care composition are generally those characterized by silicone, organic conditioning oils or combinations thereof, or those that otherwise form liquid dispersion particles in an aqueous surfactant matrix.

[0095] The one or more conditioning agents are present in amounts from about 0.01% to about 10%, from about 0.1% to about 8%, and from about 0.2% to about 4% by weight of the composition.

[0096] Silicone Conditioning Agent The composition of the present invention may contain one or more silicone conditioning agents. Examples of silicones include dimethicone, dimethiconol, cyclic silicone, methylphenylpolysiloxane, and modified silicones with various functional groups such as amino groups, quaternary ammonium salt groups, aliphatic groups, alcohol groups, carboxylic acid groups, ether groups, epoxy groups, sugar or polysaccharide groups, fluorine-modified alkyl groups, alkoxy groups, or combinations of such groups. Such silicones may be soluble or insoluble in aqueous (or non-aqueous) product carriers. In the case of insoluble liquid silicones, the polymer may be in an emulsified form with droplet sizes of about 10 nm to about 30 micrometers.

[0097] Organic Conditioning Substances The conditioning agent of the composition of the present invention may also include at least one organic conditioning substance, such as an oil or wax, either alone or in combination with other conditioning agents, such as the silicones mentioned above. The organic substance may be non-polymeric, oligomeric or polymeric. It may be in the form of an oil or wax, and may be added to the formulation as is or in a pre-emulsified form. Some non-limiting examples of organic conditioning materials include: i) hydrocarbon oils, ii) polyolefins, iii) fatty esters, iv) fluorinated conditioning compounds, v) fatty alcohols, vi) alkyl glucosides and alkyl glucosides derivatives, vii) quaternary ammonium compounds, viii) polyethylene glycols and polypropylene glycols having a molecular weight of up to about 2,000,000, such as those with the CTFA designations PEG-20 200, PEG-400, PEG-600, PEG-1000, PEG-2M, PEG-7M, PEG-14M, PEG-45M, and mixtures thereof.

[0098] Beneficial Agents The personal care composition may further comprise one or more additional benefit agents, including materials selected from the group consisting of anti-dandruff agents, anti-fungal agents, anti-itch agents, anti-microbial agents, anti-bacterial agents, moisturizers, antioxidants, vitamins, fat-soluble vitamins, fragrances, whitening agents, enzymes, sensates, attractants, dyes, pigments, bleaches, and mixtures thereof.

[0099] The personal care composition of the present invention may be present in a typical personal care formulation. The composition may be in the form of a solution, dispersion, emulsion, powder, talc, capsule, sphere, sponge, solid dosage form, foam, and other delivery mechanisms. The composition of the present invention may be a leave-on hair product, such as a hair tonic, treatment, and styling product, a rinse-off hair product, such as a hair conditioner, and a treatment product, and any other form that can be applied to hair. The personal care composition may be a hair mask, a co-wash, a hair wax, a hair clay, a hair food, a hair milk, a hair pudding, and a hair gel.

[0100] The personal care composition may be provided in the form of a porous dissolvable solid structure, such as those disclosed in U.S. Patent Application Publication Nos. 2009 / 0232873 and 2010 / 0179083, which are incorporated herein by reference in their entireties. Thus, the personal care composition comprises a chelating agent, a buffer system comprising an organic acid, from about 23% to about 75% of a surfactant, from about 10% to about 50% of a water-soluble polymer, and optionally from about 1% to about 15% of a plasticizer, such that the personal care composition is in the form of a flexible porous dissolvable solid structure, the structure having an open cell content of from about 80% to about 100%.

[0101] The personal care composition comprises a chelating agent, a buffer system including an organic acid, from about 23% to about 75% of a surfactant, wherein the surfactant has an average ethoxylate / alkyl ratio of from about 0.001 to about 0.45, from about 10% to about 50% of a water soluble polymer, and from about 1% to about 15% of a plasticizer, and the article has a mass of about 0.03 g / cm. 3 ~Approx. 0.20g / cm 3 The solid may be in the form of a porous dissolvable solid structure having a density of

[0102] The personal care composition may be in the form of a viscous liquid comprising a chelating agent, a buffer system including an organic acid, 5-20% surfactant, and a polycarboxylate rheology modifier, the polycarboxylate being specifically selected to be effective at the high electrolyte levels resulting from the incorporation of the primary buffer system and chelating agent used in the present invention. Non-limiting examples include acrylates / C10-C30 alkyl acrylate crosspolymers such as Carbopol EDT2020, 1342, 1382 from Lubrizol. The rheological benefits of these actives include stability, ease of dispensing, smoothness when spread, etc.

[0103] Personal care compositions are generally prepared by conventional methods such as those known in the art of making compositions. Such methods typically include mixing the ingredients in one or more steps to a relatively homogeneous state, with or without heating, cooling, application of vacuum, and the like. The compositions are prepared to optimize stability (physical stability, chemical stability, photostability) and / or delivery of actives. The personal care composition may be present in a single phase or a single product, or the personal care composition may be present in separate phases or separate products. When two products are used, the products may be used together, simultaneously, or sequentially. Sequential use may occur over a short period of time, such as immediately after use of one product, or over a period of hours or days.

[0104] method In vitro evaluation of antifungal efficacy Malassezia furfur (CBS 7982) is grown for approximately 24 hours in a 250 mL vented-capped polycarbonate Erlenmeyer flask containing approximately 100 mL of mDixon medium and 5 mL of fully grown M. furfur culture prepared using the same conditions as described. Cells are diluted by mixing 2.5 mL of the 24-hour culture per 50 mL of mDixon medium. Using a Versette robot (ThermoFisher Scientific), 292.5 μL of diluted cells are transferred to each well of a Beckman 267007 polypropylene round-bottom deep-well plate. All compounds are supplied by Sigma Aldrich (St. Louis, MO) and prepared as 10 mg / mL in DMSO. A semi-permeable aeraseal membrane is applied to the plate and then covered with water-soaked cotton wool. The samples are shaken at 31° C. in a Heidolph Titramax 100 shaker at 1500 rpm for approximately 72 hours. The plate is shaken at 1250 rpm in an Eppendorf MixMate shaker to disperse the cells, and then 200 μL is transferred to a Corning 3596 polystyrene plate. The samples are shaken again at 950 rpm in a MixMate shaker, and then the absorbance is read at 600 nm using a SpectraMax plate reader from Molecular Devices.

[0105] In vivo assessment of scalp health efficacy Subjects are enrolled in a double-blind randomized study for all study groups, with baseline and week 3 scalp health measurements for flake, itching, and scalp health endpoints. Subjects are given home test products and instructions on their use throughout the study. Test products are solubilized in hydroalcoholic leave-on formulations. Azoxystrobin raw material is supplied by AK Scientific Inc. (Union City, CA) as 97% or greater purity. Azoxystrobin scalp treatments are prepared from a slurry of azoxystrobin in ethanol, formulated to 0.1% (w / v) in a base chassis of 50% ethanol, 0.35% Ultrez 21 (rheology modifier), 0.05% neutrol TE, and water (qs). Vehicle scalp treatments are prepared similarly, except without the addition of azoxystrobin raw material. Subjects apply either azoxystrobin or vehicle scalp treatments daily for three weeks.

[0106] Scalp scoring is performed by a certified professional scorer on the Adhesive Scalp Flaking Score (ASFS) as described in published methods. Detailed methods can be found in Journal of Dermatological Treatment 2014,25,232-236, which is incorporated herein by reference. Briefly, subjects are assessed for severity of flaking by inspecting the scalp under illumination that mimics daylight conditions. The scalp is divided into eight sections, and each section is assessed for the presence of dandruff flakes adhering to the scalp skin using a 0-10 (increments of 2 units) scale. Ragged flakes on the hair are not considered in the scoring. The final or total ASFS is the sum of the scores for all eight scalp sections, resulting in a scale ranging from 0 to 80 units. Changes in flaking over time are reported as changes from baseline at week 3.

[0107] Biomarkers of scalp health, including inflammation, itch, oxidative stress, and barrier integrity biomarkers, are assessed by non-invasive tape strip sampling of the scalp surface to determine therapeutic recovery. All biomarkers are analyzed from D-squame® scalp tape samples collected from subjects' scalp before and after scalp treatment with either azoxystrobin or vehicle (baseline and week 3, respectively). These are extracted and analyzed according to published methods (International Journal of Dermatology 2011,50,102-113, incorporated herein by reference). Data analysis is performed using standard statistical methods and calculations. Briefly, D-Squame® tape strip samples (standard sampling disk, diameter 22 mm; CuDerm Corp., Dallas, TX, USA) tape strips are collected from each subject at each time point (baseline and 3 weeks after treatment) from the octant with the most flakes as determined by a qualified grader at the baseline flake assessment. Tape samples are collected by isolating the scalp by creating a good part in the hair (using a comb and clips). The tape is then placed over the parting and rubbed repeatedly (15-20 strokes back and forth) with the blunt end of tweezers to ensure good contact. The tape is removed and the next tape is placed in the same location, and the process is repeated until six consecutive tapes have been collected.

[0108] Human inflammatory cytokines are analyzed to evaluate skin irritation and inflammatory processes. D-Squame® tape strips sampled from human scalp are extracted with phosphate-buffered saline (PBS) containing additional 0.25 M NaCl and a commercial protease inhibitor cocktail (Roche Applied Science, Inc., Indianapolis, IN, USA) containing a mixture of protease inhibitors with broad-spectrum inhibitor specificity, on ice for 30 minutes with sonication. Multiple human cytokines (IL-1α, IL-1 RA) are quantified simultaneously using Milliplex Human Cytokine Multiplex Kit (Millipore Corp., Billerica, MA, USA). Aliquots of these extracts are analyzed for soluble protein using BCA™ Protein Assay Kit (Pierce Biotechnology / Thermo Scientific, Rockford, IL, USA) with bovine serum albumin (BSA) as reference standard. Cytokine data are reported as pg of soluble protein.

[0109] Histamine is analyzed by gradient reverse-phase HPLC / MS / MS to evaluate scalp itch. D-Squame® tape strips sampled from human scalp are placed into individual polypropylene vials, stable isotope-labeled histamine (D4-histamine) internal standard (ISTD) is added to each vial, and then extracted with acidified water (0.1% formic acid in distilled deionized water) using sonication for 10 minutes. Each extraction solution is isolated from the tape strip, and an aliquot of each sample is placed in a designated location in a 96-well polypropylene plate. A set of histamine standards is prepared in a 96-well polypropylene plate across the appropriate calibration range in acidified water and spiked with ISTD. Standards and extracts of scalp tape strips are analyzed using gradient reverse-phase HPLC / MS / MS. Histamine and ISTD are monitored by positive ion electrospray (ESI) using multiple reaction monitoring with precursor ions at 112 m / z (histamine) and 116 m / z (ISTD) and product ions at 95 m / z (histamine) and 99 m / z (ISTD). Standard curves are constructed by plotting the signals, where the standard curve is defined as the mass of histamine in the corresponding standard versus the peak area ratio of each standard (peak area histamine / peak area ISTD). The generated regression equation is then used to back-calculate the mass of histamine in the calibration standards and human scalp extract samples. Results are reported as mass of histamine (ng) per μg of protein found in tape strip extracts as determined using the BCA™ Protein Assay Kit (Pierce Biotechnology / Thermo Scientific, Rockford, IL, USA).

[0110] S100A12 protein is analyzed to determine the effect of scalp treatment on active inflammatory disease. D-Squame® tape strips sampled from human scalp are extracted with standard extraction buffer, and the extracts are analyzed with a custom antibody kit for S100A12 from Meso Scale Discovery (Rockville, MD). The amount of S100A12 obtained is also standardized by dividing by the amount of soluble protein measured in the tape strip extract.

[0111] Myeloperoxidase protein is analyzed to determine the effect of scalp treatment on oxidative stress and potential oxidative damage. D-Squame® tape strips sampled from human scalp are extracted with a standard extraction buffer, and the extracts are analyzed with a myeloperoxidase immunoassay kit from Meso Scale Discovery (Rockville, MD). The amount of myeloperoxidase obtained is also standardized by dividing by the amount of soluble protein measured in the tape strip extract.

[0112] Biochemical markers of skin / scalp barrier integrity are analyzed to assess improvements to barrier health. Human scalp D-Squame® tape strip samples are extracted with PBS containing 0.2% SDS and 0.5% propylene glycol (PG) for 30 minutes with sonication on ice. Human skin analytes (keratin 1, keratin 10, human serum albumin) are quantified simultaneously using a 3-plex Human Skin Panel LINCOplex Kit (Millipore Corp.). Soluble protein is measured using a BCA™ Protein Assay Kit. Barrier integrity data is reported as either pg or ng per μg soluble protein.

[0113] Each subject is administered a self-assessment questionnaire on itch perception at baseline and week 3. Itch perception is quantified by each subject as the severity of symptoms over the past 24 hours on a 7-point scale: 0=none, 1=slight, 2=slight-moderate, 3=moderate, 4=moderate-severe, 5=severe, 6=very severe.

[0114] result Antifungal efficacy The following data demonstrate that azoxystrobin is unique among other strobilurins in its exceptionally potent antifungal efficacy against yeasts of the genus Malassezia. Azoxystrobin exhibited a minimum inhibitory concentration (MIC) of 0.39-0.49 ppm against M. furfur, which is four times more potent than the next most potent strobilurin, pyraclostrobin (1.95 ppm), and eight times more potent than zinc pyrithione (3.13 ppm), a commonly used antifungal-based antidandruff active. Orysastrobin, another strobilurin antifungal used in agriculture, yielded an MIC of 31.25 ppm, 64 times less potent than azoxystrobin.

[0115] [Table 1]

[0116] Scalp peeling The following data demonstrates the ability of azoxystrobin to reduce scalp flakes for the benefit of scalp and hair. The change from baseline in scalp flakes score (ASFS) is analyzed using an analysis of covariance (ANCOVA) model. This model includes treatment, test site, sex, baseline measurement, and age as covariates. Azoxystrobin reduces the sticky scalp flakes score (ASFS) by 4.7 units more than placebo (no azoxystrobin) after 3 weeks of treatment (p=0.002). The dandruff clinical population in this example that completes the study and is evaluated based on compliance with enrollment criteria and study procedures is 53% female and 47% male. The overall flakes results reflect the efficacy of treatment response with proven efficacy for both male and female subjects.

[0117] [Table 2]

[0118] inflammation The following data demonstrate that azoxystrobin significantly reduces pro-inflammatory biomarkers of scalp health in consumers after 3 weeks of treatment. The ratio of interleukin-1 receptor antagonist to interleukin-1 (IL-1RA:IL-1a), which has been established to be elevated in dandruff as an indicator of unhealthy scalp, is reduced by treatment with azoxystrobin. Azoxystrobin scalp treatment also significantly reduces levels of S100A12, a cytokine-like antimicrobial peptide expressed in inflammatory diseases, compared to placebo controls (p=0.1042).

[0119] [Table 3] * indicates significant differences between treatments (P<=0.20).

[0120] [Table 4] *indicates significant differences between treatments (P<=0.20).

[0121] Itching The following data shows that azoxystrobin does not significantly reduce histamine compared to placebo control or baseline value.Nevertheless, the subjects in azoxystrobin treatment group perceive scalp itch reduction, which is significantly improved from baseline itch severity and the itch severity perceived by the subjects in placebo control treatment group.This shows that azoxystrobin can provide benefits in terms of itch, surprisingly, but does not have the function of reducing itch through the histamine-dependent pathway of scalp itch and the reduction of histamine in dandruff sufferers, which has already been proven to be directly proportional to the reduction of itch perception.

[0122] [Table 5]

[0123] [Table 6] * p-value = 0.05 for treatment mean pairwise comparisons between azoxystrobin and vehicle

[0124] Oxidative stress The following data demonstrate that azoxystrobin significantly reduces myeloperoxidase, a biochemical marker of oxidative stress, after three weeks of treatment. Myeloperoxidase is an enzyme that is elevated as part of the immune response that defends against microbial pathogens. Its chemical defense against pathogens, including Malassezia, involves the production of hypochlorous acid, a powerful oxidant that exerts a biocidal function, but also produces toxic reactive oxygen species that can cause collateral tissue damage. Oxidative stress and the resulting scalp tissue damage have established effects on both scalp health and hair health (International Journal of Trichology 2018,10,262-270, incorporated herein by reference). Reduction of scalp myeloperoxidase by azoxystrobin indicates a benefit in reducing oxidative damage to the scalp that impacts on scalp and hair health.

[0125] [Table 7] * indicates significant differences between treatments (P<=0.20).

[0126] Epidermal barrier health Scalp treatment with azoxystrobin significantly modulates biochemical markers of epidermal barrier integrity as an indicator of scalp health benefits. An intact epidermal barrier is the first line of defense against bacteria, fungi, pollution, and other environmental insults. Azoxystrobin significantly reduces human serum albumin (HSA), indicating that the scalp barrier is less leaky and permeable to external aggressions. Azoxystrobin also significantly increases keratin 1 and 10 compared to placebo controls, an indicator of improved epidermal barrier composition and function.

[0127] [Table 8] * indicates significant differences between treatments (P<=0.20).

[0128] The present invention is directed to the use of azoxystrobin to reduce the number of flakes on a surface.The present invention is directed to the use of azoxystrobin to reduce surface itching as perceived by a user.The present invention is directed to the use of azoxystrobin to reduce the level of myeloperoxidase on a surface as an indicator of reduced oxidative stress and damage.The present invention is directed to the use of azoxystrobin, wherein the surface is selected from the group consisting of skin, scalp, or human scalp, and mixtures thereof.

[0129] The present invention is directed to the use of azoxystrobin with a 4.7 unit reduction in adhesive scalp flaking score (ASFS), a 45% reduction in flaking compared to a placebo control, and a 30% reduction in flaking after 3 weeks of treatment. The present invention is directed to the use of azoxystrobin with a 58% reduction in interleukin-1 (IL-1RA: IL-1α) compared to a placebo control. The present invention is directed to the use of azoxystrobin with a 71% reduction in S100A12 levels compared to a placebo control. The present invention is directed to the use of azoxystrobin with an improved scalp health barrier with a 54% reduction in human serum albumin (HSA) change from baseline. EXAMPLES

[0130] Non-limiting examples The shampoo compositions illustrated in the following examples are prepared by conventional formulation and mixing methods. All exemplified amounts are listed as weight percentages on an active basis and exclude minor materials such as diluents, preservatives, etc., and color percentages are by weight unless otherwise specified.

[0131] [Table 9]

[0132] All above are on an activity basis. For example, for 11% SLE1S, 44% of a 25% active SLE1S solution should be added. The table below explains each of the notes in the table above.

[0133] [Table 10]

[0134] The following examples further describe and demonstrate non-limiting examples within the scope of the present invention. These examples are provided for illustrative purposes only and should not be construed as limiting the present invention, since many variations thereof are possible without departing from the spirit and scope of the present invention. Where applicable, ingredients are identified by chemical or CTFA name, or otherwise defined below.

[0135] [Table 11]

[0136] [Table 12] 1 Pride Solvents SD-40B 200 Alcohol 2. Ashland Flexithix 3 Ashland Benecel K200M 4. Structure XL by AkzoNobel 5. Menthol from Kerry Ingredients and Flavors 6. Niacinamide from Lonza 7. Caffeine from Merck 8. D-Panthenol by BASF 9. Cremophor RH-40 by BASF 10 Propylene glycol from Sigma Aldrich

[0137] combination Paragraph A Use of azoxystrobin to reduce the number of flakes on a surface.

[0138] Paragraph B. Use of azoxystrobin as described in Paragraph A to reduce superficial itching as perceived by a user.

[0139] Paragraph C. Use of azoxystrobin as described in Paragraphs A-B to reduce the level of myeloperoxidase in the surface as an indicator of reduced oxidative stress and damage.

[0140] Paragraph D. The use of azoxystrobin according to Paragraphs A-C, wherein the surface is selected from the group consisting of skin, scalp, or human scalp, and mixtures thereof.

[0141] Paragraph E The use of azoxy according to paragraphs AD, wherein the surface is selected from the group consisting of skin, scalp, or human scalp, and mixtures thereof.

[0142] Paragraph F. The use of azoxystrobin according to Paragraphs A-E, wherein the surface is selected from the group consisting of skin, scalp, or human scalp, and mixtures thereof.

[0143] Paragraph G. The use of azoxystrobin according to paragraphs A-F, wherein the level of azoxystrobin is from about 0.01% to about 10%.

[0144] Paragraph H The use of azoxystrobin according to paragraphs A to G, wherein the level of azoxystrobin is from about 0.01% to about 10%.

[0145] Paragraph I The use of azoxystrobin according to paragraphs AH, wherein the level of azoxystrobin is from about 0.01% to about 10%.

[0146] Paragraph J The use of azoxystrobin according to Paragraphs AI, wherein the azoxystrobin is applied from a personal care composition.

[0147] Paragraph K The use of azoxystrobin according to Paragraphs A-J, wherein the azoxystrobin is applied from a personal care composition.

[0148] Paragraph L The use of azoxystrobin according to Paragraphs A-K, wherein the azoxystrobin is applied from a personal care composition.

[0149] Paragraph M The use of azoxystrobin according to Paragraphs A-L, wherein the personal care composition is selected from the group consisting of a leave-on treatment, a shampoo, or a conditioner.

[0150] Paragraph N The use of azoxystrobin according to Paragraphs A-M, wherein the personal care composition is selected from the group consisting of a leave-on treatment, a shampoo, or a conditioner.

[0151] Paragraph O The use of azoxystrobin according to Paragraphs A-N, wherein the personal care composition is selected from the group consisting of a leave-on treatment, a shampoo, or a conditioner.

[0152] Paragraph P The use of azoxystrobin according to Paragraphs A-O, wherein the personal care composition is selected from the group consisting of a leave-on treatment, a shampoo, or a conditioner.

[0153] Paragraph Q The use of azoxystrobin according to Paragraphs A-P, wherein the personal care composition is selected from the group consisting of a leave-on treatment, a shampoo, or a conditioner.

[0154] Paragraph R The use of azoxystrobin according to Paragraphs A-Q, wherein the personal care composition is selected from the group consisting of a leave-on treatment, a shampoo, or a conditioner.

[0155] Paragraph S Use of azoxystrobin as described in paragraphs A-R to achieve a 4.7 unit reduction in Adhesive Scalp Flaking Score (ASFS), a 45% reduction in flaking compared to a placebo control, and a 30% reduction in flaking after 3 weeks of treatment.

[0156] Paragraph T The use of azoxystrobin as described in paragraphs A-S, wherein interleukin-1 (IL-1RA:IL-1α) is reduced by 58% compared to a placebo control.

[0157] Paragraph U The use of azoxystrobin as described in paragraphs A-T, wherein S100A12 levels are reduced by 71% compared to a placebo control.

[0158] Paragraph V The use of azoxystrobin as described in paragraphs A-U, whereby the scalp health barrier is improved by a 54% reduction in human serum albumin (HSA) as changed from baseline.

[0159] Paragraph W The use of azoxystrobin as described in paragraphs A-V, wherein keratins 1 and 10 are increased by 86% compared to a placebo control.

[0160] Paragraph X The use of azoxystrobin as described in paragraphs A-W, wherein the itch perception is reduced by 48% compared to a placebo control.

[0161] Paragraph Y The use of azoxystrobin as described in paragraphs A-X, wherein myeloperoxidase is reduced by 64% compared to a placebo control.

[0162] Paragraph Z The use of azoxystrobin according to Paragraphs A-Y, wherein the personal care composition further comprises from 2% to 50% of one or more anionic surfactants.

[0163] Paragraph AA The use of azoxystrobin according to Paragraphs A-Z, wherein the personal care composition further comprises from 2% to 50% of one or more anionic surfactants.

[0164] Paragraph BB The use of azoxystrobin according to Paragraphs A-AA, wherein the personal care composition further comprises from 2% to 50% of one or more anionic surfactants.

[0165] Paragraph CC The use of azoxystrobin according to Paragraphs A-BB, wherein the personal care composition further comprises a nonionic, amphoteric, cationic, or zwitterionic surfactant, and mixtures thereof.

[0166] Paragraph DD The use of azoxystrobin according to Paragraphs A-CC, wherein the personal care composition further comprises a nonionic, amphoteric, cationic, or zwitterionic surfactant, and mixtures thereof.

[0167] Paragraph EE The use of azoxystrobin according to Paragraphs A-CD, wherein the personal care composition further comprises a nonionic, amphoteric, cationic, or zwitterionic surfactant, and mixtures thereof.

[0168] Paragraph FF The use of azoxystrobin according to Paragraphs A-EE, wherein the personal care composition further comprises a cationic polymer.

[0169] Paragraph GG The use of azoxystrobin according to Paragraphs A-FF, wherein the personal care composition further comprises a cationic polymer.

[0170] Paragraph HH The use of azoxystrobin according to Paragraphs A-GG, wherein the personal care composition further comprises a cationic polymer.

[0171] Paragraph II The use of azoxystrobin according to Paragraphs A-HH, wherein the personal care composition further comprises a conditioning agent.

[0172] Paragraph JJ The use of azoxystrobin according to Paragraphs A-II, wherein the personal care composition further comprises a conditioning agent.

[0173] Paragraph KK The use of azoxystrobin according to Paragraphs A-JJ, wherein the personal care composition further comprises a conditioning agent.

[0174] Product form The personal care composition of the present invention may be present in a typical personal care formulation.The composition may be in the form of a solution, dispersion, emulsion, powder, talc, capsule, sphere, sponge, solid dosage form, foam, and other delivery mechanisms.The composition of the present invention may be in the form of leave-on hair products, such as hair tonics, treatment and styling products, rinse-off hair products, such as shampoos, pre-wash products, co-wash products, and personal cleansing products, and treatment products, and any other form that can be applied to hair or skin.

[0175] Dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​recited. Instead, unless otherwise indicated, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm."

[0176] In addition to the above, the invention includes as additional aspects all embodiments of the invention narrower in any way than the variations specifically mentioned above. With respect to aspects of the invention described as genus, all individual species are considered to be separate and independent aspects of the invention. With respect to aspects of the invention described or claimed with "a" or "an", these terms should be understood to mean "one or more", unless a more restrictive meaning is clearly required by the context. With respect to elements described as one or more within a set, it should be understood that all combinations within the set are contemplated. When aspects of the invention are described as "comprising" a feature, it is also contemplated that the embodiment "consisting of" or "consisting essentially of" that feature.

[0177] All documents cited in the Detailed Description are, in relevant part, incorporated herein by reference. The citation of any document should not be construed as an admission that it is prior art to the present invention. To the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall control.

[0178] While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims

[Claim 1] 1. A method for reducing the number of flakes on a surface by applying a composition comprising 0.01% to 10% azoxystrobin to said surface selected from the group consisting of skin, scalp, or human scalp, and mixtures thereof, comprising: A method in which the Adhesive Scalp Flaking Score (ASFS) is reduced by 4.7 units, resulting in a 45% reduction in flaking compared to a placebo control, and a 30% reduction in flaking after 3 weeks of treatment.

Images